Strados Labs positions itself as a “respiratory endpoint intelligence company,” primarily serving pharmaceutical companies, biotech firms, and CROs for Phase I-IV respiratory clinical trials. Its Endpoint Suite brings together continuous cough monitoring, remote/on-site spirometry, FeNO, lung sound analysis, and eCOA into a single solution, while incorporating the clinical trial capabilities of NuvoAir.
The product portfolio includes the RESP® Biosensor, RESP® Watch, Air Next Spirometer, NObreath® FeNO, and eCOA modules. Its differentiation is not just data collection, but an emphasis on AI event detection, expert human review, audio retention, annotation, and audit trails, with the goal of producing respiratory endpoint data suitable for regulatory submissions. The materials also mention live flow curve monitoring for quality control during spirometry maneuvers, supporting ATS 2019 compliance.
Public information indicates that it has FDA 510(k), CE Mark, ISO 13485, and HIPAA compliance credentials, and highlights GCP-compliant workflows. The company says it has supported 55+ clinical studies across 34 countries, and can provide site support, device logistics, and global project delivery, which is valuable for multinational clinical trials. However, details on permission systems, data residency, encryption, SLAs, and self-hosted deployment are not disclosed.
The website does not list plans, pricing, free trials, or payment methods, making it clearly a project-based, business-negotiation procurement model. For CROs, it emphasizes serving as a single integration point and complementing broader eClinical infrastructure, but it does not list specific third-party integrations, APIs, or developer documentation, so technical integration transparency is limited.
Its strengths are comprehensive respiratory endpoint coverage, relatively strong clinical and regulatory evidence, and reduced risk from coordinating multiple vendors. Its drawbacks are opaque pricing, a highly vertical use case, and limited suitability for general corporate health management or generic SaaS procurement. It is best suited to pharmaceutical companies, CROs, and clinical operations teams that need research endpoints for COPD, asthma, chronic cough, IPF, and similar areas.
The materials do not provide information on access from mainland China, RMB payment, local data compliance, or local support, so this remains unknown. If conducting clinical trials in China, additional confirmation is needed regarding network connectivity, device import/registration, cross-border data transfer, ethics requirements, and NMPA-related submissions, while also evaluating local CRO or eClinical vendor alternatives.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on stradoslabs.com official site.
stradoslabs.com is an United States SaaS Tools provider. TG4G tracks its product information, an overall rating of 7.0/10, and a China-accessibility score of Workable. Click "Visit Official Site" to reach stradoslabs.com directly.